Information sent to healthcare professionals in October 2008 about the safety of medicines

Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.

A list of letters sent to healthcare professionals in October 2008, to inform of new safety information and advice.

 

Date issued
Product
Safety information
02/10/2008

Updated and strengthened safety recommendations:

  • Do not use in patients with high blood pressure persistently elevated above 140/90 mm/Hg and which is not adequately controlled
  • All patients who start treatment should have blood pressure monitored within 2 weeks of starting and periodically thereafter
05/09/2008

Suspension of marketing authorisation because of concerns about psychiatric side-effects:

  • Do not issue, renew, or dispense any prescriptions for rimonabant

See also: https://www.cas.dh.gov.uk/Home.aspx


Page last modified: 03 November 2008